Gossamer Bio (GOSS) Stock
What Gossamer Bio's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -0.68x
- Revenue growth
- +32.4%
- Operating margin
- -311.7%
What Gossamer Bio's price implies
Gossamer Bio's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Gossamer Bio's 10-K filings.
Gossamer Bio revenue and free cash flow
FY2017–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $115M | $48M |
| Net income | -$234M | -$229M | -$180M | -$57M | -$170M |
| Free cash flow | -$190M | -$187M | -$159M | -$3M | -$171M |
| EPS (diluted) | -$3.13 | -$2.71 | -$1.18 | -$0.25 | -$0.75 |
| Operating margin | — | — | — | -52.2% | -352.2% |
Superinvestors who own GOSS
From each investor's latest 13F filing (what a 13F shows). All 10 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| David Shaw D. E. Shaw & Co. | Added | $7M | 0.00% | Q2 2026 |
| Cliff Asness AQR Capital Management | Added | $3M | 0.00% | Q2 2026 |
| Jim Simons Renaissance Technologies | Added | $2M | 0.00% | Q2 2026 |
| Arrowstreet Capital Arrowstreet Capital | New position | $1M | 0.00% | Q2 2026 |
| Two Sigma Two Sigma Investments | Added | $1M | 0.00% | Q2 2026 |
| Zhang Lei Hillhouse (HHLR Advisors) | Held | $818,727 | 0.10% | Q2 2026 |
| Paul Marshall Marshall Wace | New position | $338,399 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors | Trimmed | $238,831 | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp | Added | $78,939 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management | Trimmed | $52,000 | 0.0% | Q3 2026 |
Gossamer Bio insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of GOSS in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from GOSS's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Gossamer Bio compares
Gossamer Bio's revenue growth is higher than 77% of Healthcare companies and 85% of the 3,493 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 77% | 85% |
| Operating margin | 14% | 5% |
Questions about Gossamer Bio
Are Gossamer Bio insiders buying the stock?
No open-market insider purchases of GOSS in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Gossamer Bio?
10 of the superinvestors Investingly tracks hold GOSS in their latest 13F, including David Shaw, Cliff Asness, Jim Simons.
Companies like Gossamer Bio
Travere Therapeutics Inc (TVTX)$4.7BDianthus Therapeutics Inc. (DNTH)$4.8BCrispr Therapeutics AG (CRSP)$4.8BEdgewise Therapeutics Inc (EWTX)$4.9BErasca Inc (ERAS)$4.5BDefinium Therapeutics, Inc. (DFTX)$4.5BPTC Therapeutics Inc (PTCT)$5.5BCogent Biosciences Inc (COGT)$5.5BLegend Biotech Corp (LEGN)$4.1B All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.